AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02205749 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Study-specific consent model
Description: • Review plain language brochure describing consent to a biobank based on the study-specific model of consent
Study NCT02205749 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Broad consent model
Description: • Review plain language brochure describing consent to a biobank based on the broad model of consent
Study NCT02205749 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Notice consent model
Description: • Review plain language brochure describing consent to a biobank based on the notice model of consent
Study NCT03957837 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical nerve sheath diameter ultrasound measurement
Description: In cases: ultrasound measurement of the diameter of the optical nerve sheath at (T1) baseline before the induction of general anesthesia (5 min after the beginning of mechanical ventilation in supine position); (T2) after 10 min from 25 degrees head down positioning and with pneumoperitoneum insufflation; (T3) after 60 min from T2, in head down position; (T4) after 10 min from tracheal tube removal, in supine position.~In healthy controls: ultrasound measurement of the diameter of the optical nerve sheath at (T1) baseline in supine position; (T2) after 10 min from 25 degrees head down positioning; (T3) after 60 min from T2, in a head down position; (T4) after 10 min from positioning supine
Study NCT03616678 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VenTouch System
Description: The VenTouch™ System consists of a delivery tool with a pre-loaded implant (VenTouch device) and accessories, which include a sizing tool, PEMS, chamber positioning tool, and accessories kit with luer fitting, tubing clamp, and titanium plug. The VenTouch device is offered in 6 sizes, with 4 different sized inflatable chambers available. Please refer to the VenTouch Instructions for Use for and system details.~The VenTouch device consists of three (3) inflatable silicone chambers attached to the wall of a knitted polyester support. The VenTouch device is implanted around the base of the heart and positioned at the level of the atrio-ventricular (AV) groove and the adjacent ventricular muscle. The VenTouch device is composed of biocompatible, medical-grade silicone and polyester.
Study NCT03504878 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic appendectomy
Description: The laparoscopic appendectomy was performed with three trocars. Pneumoperitoneum was created using an open Hasson technique. The mesoappendix was divided using a harmonic scalpel or endoscopic tissue fusion device. The appendix was divided by placing one endoscopic loop and cut with harmonic scalpel. The specimen was removed through the umbilical port.
Study NCT03504878 — intervention group
Intervention type: PROCEDURE
Intervention: Open appendectomy
Description: The open appendectomy was carried out in the standard way with McBurney muscle splitting incision.
Study NCT02355288 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally Invasive Coronary Bypass
Description: Bypass graft of the Left Anterior Descending (LAD) artery using minimally invasive cardiac surgery. MICS is a bypass surgery done with a small (4-6 cm) incision under the left breast, instead of the usual incision down the middle the chest.
Study NCT02355288 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutenous Coronary Intervention
Description: Stenting of the Left Anterior Descending (LAD) artery using a drug-eluting stent.
Study NCT02597946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib
Study NCT02597946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT04448587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100mg
Description: Oral sitagliptin will be commenced at a dose of 100 mg BID. The dose will be increased by 100 mg every three days up to a maximal dose of 300 mg BID. In the case of significant drug related side effects or drug intolerance, the last tolerated dose will be resumed. Patients responding well to lower doses of sitagliptin, will not be given higher doses of the drug. Sitagliptin will be provided as long as deemed effective by the treating physician up to three months.
Study NCT03105687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS reminders of medicines intake
Description: The intervention consists of daily SMS reminders of blood pressure-lowering medication provided by a pharmacist for a period of 3 months.
Study NCT03766048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-Anterior-Mesh, SAM
Description: laparoscopic sacropexy is only performed with the anterior mes
Study NCT03766048 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Double-Mesh, DM
Description: laparoscopic sacropexy is performed using two synthetic non-absorbable meshes, both sutured to the promontory (Double-Mesh, DM): one mesh is placed in the vesicovaginal space and sutured to the uterine cervix or vaginal apex, and one mesh is placed in the rectovaginal space
Study NCT02915081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blue light
Description: Illumination: High illumination lighting will be instituted with a Day\*Light Classic Light (Uplift Technologies, Dartmouth, NS)~Blue wavelength: Each subject will be fitted with blue filtered goggles (Lee Filters, Burbank, CA). These goggles ensure the transmission of a bright (1700 lux) blue (peak 442 nm) spectrum light when the subject is within 12 inches.~Photoperiod: A 24-hour photoperiod will be used that commences at 0800 the morning prior to surgery and continues for 24 hours. To account for potential variability in the exposure of interest, each subject will complete a diary to catalogue duration and distance of light exposure. Postoperatively the same photoperiod will be instituted and continued for one 24 hour period.
Study NCT02730884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rigosertib
Description: Participants take 560 mg Rigosertib by mouth in the morning (two 280 mg capsules) and 560 mg Rigosertib in the afternoon.
Study NCT02730884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Quality of life questionnaire completed on Day 1 of Cycle 1. It should take about 10-15 minutes to complete.
Study NCT03157427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRYOBEAUTY MAINS
Description: CYOBEAUTY MAINS diffuses Difluoroethane gas to the skin. The administration of the cryogenic gas is temperature controlled, accurate and contactless (by means of a spray nozzle), in small quantity (\<1g) and during a predetermined short duration (3 seconds)
Study NCT04313127 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular other name:Ad5-nCoV
Study NCT02823691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide and Metformin
Description: Lanreotide and Metformin
Study NCT04349527 — intervention group
Intervention type: PROCEDURE
Intervention: Round-block Oncoplastic Breast Conserving Surgeries
Description: We de-epithelize the gap between the double round-lines, and we dissect the dermis from the best localization where we can reach the tumor. If the tumor located close to the skin then we are not performing de-epithelization, we excise it with the skin. We mark every wall of the tumor bed with clips. We dissect the surrounding parenchyma- so called parenchyma pillars- from the pectoral fascia and the skin, and we mobilize it. The line under the skin means, the layer under the subcutis, above the superficial fascia, so gives appropriate blood supply to the skin. After this the incision line should be placed 5 mm from the outer round line, so a dermis pillar should be left, and the skin is dissected from the parenchyma as needed. The outer round line should be tightened with a non-absorbable running Benelli suture to fit the areola then interrupted sutures placed to make tensionless the running intracutaneous suture.
Study NCT04349527 — intervention group
Intervention type: PROCEDURE
Intervention: Retroglandular Oncoplastic Breast Conserving Surgeries
Description: We incise the skin slightly lateral in the IMF, around 7 cm long. We dissect with electrocauther the parenchyma with the pectoral fascia from the pectoralis major muscle at least until the mamilla. We incise the fascia along with the parenchyma which contains the tumor and macroscopically 10 mm safe zone. If the tumor is palpable, we turn the parenchyma slightly inside-out, if not, we localize it at the maximum measurement detected according to the ROLL labeling. After marking the tumor bed, we directly adapt the surrounding parenchyma pillars with absorbable sutures, or inverting sutures, or if it requires, we adapt the tumor bed with so-called dual plane mobilization. After revision, we close the fascia with absorbable running suture over the Redon drain then subcutaneous running suture with absorbable suture and finally intracutaneous skin closure.
Study NCT00216411 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Study NCT00216411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01998828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: Momelotinib tablet administered orally once daily
Study NCT05088304 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT01661140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate (stable dose)
Description: Methotrexate (MTX) was administered weekly according to the subject's pre-study MTX dose
Study NCT01661140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: 8 mg/kg intravenously every 4 weeks for 72 weeks
Study NCT01661140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 8 mg/kg intravenously every 4 weeks for 72 weeks
Study NCT01661140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (tapering dose)
Description: Tapering doses of methotrexate (MTX) were administered weekly from Week 24 to Week 56. Tapering doses depended on dose administered to the subject during the open label period. First tapering occurred at randomization (Week 24), second tapering at Week 32, third tapering at Week 40 and final tapering at Week 48.
Study NCT01554280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fully coated, removable , self-expanding oesophageal stent
Description: Insertion of the fully coated, removable, self-expanding oesophageal stent for the prevention of oesophageal strictures.
Study NCT01240642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA404
Study NCT03258112 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiofrequency cardiac catheter ablation
Description: procedure used for ablation of ventricular arrhythmia using catheters introduced to target sites percutaneously through venous or arterial systems using radiofrequency power
Study NCT04295161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Abiraterone acetate immediate release formulations
Study NCT04295161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate
Description: Abiraterone acetate immediate release formulations
Study NCT01391000 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LASER CO2
Description: The therapy is performed with the patient sitting, place the unit high above the shoulder with the following indicators: through a pulsed 40 Hz, distance between device and patient 60 cm, 10x15 cm area of application, power 2W; energy between 10 and 15 J/cm2
Study NCT01391000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: Transcutaneous Electrical Nerve Application of Stimulation occurs through the use of No. 3 channels (long head of biceps area (CLB), the supraspinatus muscle area, the area medial border of the scapula.~Duration: Twenty (20) minutes, mpulsi: 70 microsec, frequency: 100 Hz, intensity: between 20 and 40 mA.
Study NCT02918864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions.
Study NCT02918864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognitive Skills Training
Description: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Study NCT02918864 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facilitated Play Therapy
Description: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Study NCT05572762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cannula plastic part while applying peribulbar block
Description: Using the cannula and introducing it peribulbar to apply regional ophthalmic anesthesia avoiding by this causing trauma to the globe, as the normal globe consistency is marble-like, the cannula can't puncture except in case of presence of staphyloma, so the cannula will either curve around it or will be kinked causing failure of the technique.
Study NCT05572762 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional technique
Description: the patients are going to receive the local anesthetic standard of care technique by using 23- or 24-gauge needle introduced through the skin extra-conal and local anesthetic solution will be injected with volume AND concentration according to the surgery going to be done
Study NCT02872623 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Enterography-MRI without enteroclysis
Study NCT02872623 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: enteroCT with enteroclysis
Study NCT01733472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GA-arm, remifentanil
Description: Remifentanil and propofol will be delivered intravenously via TCI pumps according to the Marsh and Minto algorithm
Study NCT01733472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RA-arm
Description: Intrathecal (i.e. spinal) anesthesia with isobaric bupivacaine 15 mg administered intrathecally at L4-L5.
Study NCT02887391 — intervention group
Intervention type: OTHER
Intervention: No intervention - observational study
Description: No intervention - observational study
Study NCT02755857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lozanoc
Description: 65 mg
Study NCT00737867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Day 1: Vinorelbine capsules 60 mg/m2 Day 8: Vinorelbine capsules 60 mg/m2
Study NCT00737867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Day 1: Gemcitabine infusion 1000 mg/m2 Day 8: Gemcitabine infusion 1000 mg/m2
Study NCT00737867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Day 1: Vinorelbine capsules 60 mg/m2 Day 8: Vinorelbine capsules 60 mg/m2
Study NCT00737867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Day 1: Carboplatin infusion AUC = 5 (Calvert's formula)
Study NCT02977195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP137 DL and RP2D
Description: DOSE ESCALATION PART: 7 DL: NP137 was administrated every 2 weeks, as single agent by intravenous injection over 90 min with up to 7 ascending dose levels: Dose level 1: 1 mg/kg Dose level 2: 2 mg/kg Dose level 3: 4 mg/kg Dose level 4: 6 mg/kg Dose level 5: 9 mg/kg Dose level 6: 14 mg/kg Dose level 7: 20 mg/kg~EXPANSION PARTS: NP137 was administered every 2 weeks, as single agent by intravenous injection over 180 min at 14 mg/kg (RP2D defined in the Dose escalation part).~FOR ALL PARTS AND COHORT: Treatment will be administered as long as patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Study NCT04018911 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid with standard Noise Reduction (NR_1)
Description: Hearing Aid with standard Noise Reduction (NR) Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs (ensures exact same hearing loss compensation for each intervention). Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The active comparator condition is the state of the art Noise Reduction principle.
Study NCT04018911 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid with NR_2
Description: Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions (novel NR principle) vary in their parametrization to result in different degrees of noise suppression and good speech quality.
Study NCT04018911 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid with NR_3
Description: Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions (novel NR principle) vary in their parametrization to result in different degrees of noise suppression and good speech quality.
Study NCT04018911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hearing Aid with NR_4
Description: Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. This experimental condition combines standard NR and novel NR principle to result in different degrees of noise suppression and good speech quality.
Study NCT00767377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOF5
Description: epirubicin 50 mg/m2 day 1, oxaliplatin 130 mg/m2 day 1, and 5-FU 375-425 mg/m2/d day 1 through 5 continuous infusion, repeated every 3 weeks
Study NCT00505466 — intervention group
Intervention type: BEHAVIORAL
Intervention: Genetic Counseling
Description: Genetic counseling conducted in person, by telephone with an M. D. Anderson Genetic Counselor, or with a local Genetic Counselor in conference with the M. D. Anderson Genetic Counselor.
Study NCT04462952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib (AZD1775)
Description: Adavosertib taken orally
Study NCT02158780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scrotal Orchidopexy
Description: Single incision
Study NCT02158780 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Inguinal Orchidopexy
Description: Double Incision (Standard)
Study NCT04619485 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 LASER
Description: 5 SESSIONS OF CO2 VAGINAL LASER
Study NCT04619485 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CO2 SHAM LASER
Description: 5 SESSIONS OF CO2 VAGINAL SHAM LASER
Study NCT04940143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type-A (Onabotulinum toxin type-A)
Description: Botulinum toxin-A (Onabotulinum toxin type-A/Botox®) injection will be administered from three different points, two on the medial head of the gastrocnemius muscle and one point on the lateral head with total 3-6 units/kg dose, under the guidance of electrical stimulation for the detection of the target neuromuscular junction.
Study NCT04940143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: After the botulinum toxin-A injection, the patients will be included in the comprehensive physiotherapy program thrice a week for a total of 12 weeks. The physiotherapy program will be consisted of the ankle range of motion and stretching, strengthening of the antagonist muscles, proprioception exercises, functional walking training and static and dynamic balance training.
Study NCT01965132 — intervention group
Intervention type: DRUG
Intervention: Biologic or targeted synthetic DMARD
Study NCT01192022 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TachoSil®
Description: Intraoperative application as secondary hemostatic treatment
Study NCT01192022 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgicel® Original
Description: Intraoperative application as secondary hemostatic treatment
Study NCT02830880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FACBC PET-CT
Description: Anti-3-\[18F\]FACBC is an investigational positron emission tomography (PET) radiotracer being studied given intravenously prior to PET scan.